Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Nanopath logo — Diagnostics for women.

Nanopath

Diagnostics for women.

Founded 2019 United States Cambridge, United States 18 employees Grant Total: $14.26M Biotechnology

General Information

Company Name Nanopath
Founded Year 2019
Location United States Cambridge, United States +1
Employees 18
Industries Biotechnology
Funding Stage Grant
Social

Get notified when Nanopath moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Nanopath

Nanopath is a biotechnology startup founded in 2019 with the mission to revolutionize traditional testing methodologies in molecular diagnostics for women. Their slogan, "Diagnostics for women." encapsulates their goal to enhance women's health by delivering detailed and actionable information, all within a single office visit.

Their most recent achievement includes a significant $10.00M Series A investment secured on 09 August 2022. This funding round was led by a cohort of esteemed investors, including GingerBread Capital, Norwest Venture Partners, Alumni Ventures Blockchain Fund, Green D Ventures, Undeterred Capital, and Medtech Convergence Fund.

Strongly positioned in the United States, Nanopath's innovative approach to diagnostics holds great promise for both the healthcare industry and potential investors seeking opportunities in the biotechnology sector.

Taxonomy: molecular diagnostics, women's health, diagnostic testing, nanotechnology, clinical data, precision medicine, disruptive technology, medical diagnostics

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Grant •••••• 2
Investor
•••• •••• 		21 May 2024
Series A •••••• 6
Investor Investor Investor Investor
•••• •••• 		09 Aug 2022
Grant •••••• 2
Investor Investor
21 Dec 2021

Nanopath Alternatives & Competitors

Nanopath vs
Abrites
Abrites Bulgaria

Achieve the impossible.

52 employees
Manufacturing
Nanopath vs
Eclipse Diagnostics
Eclipse Diagnostics United Kingdom

UK's leading supplier of multi-brand vehicle diagnostic equipment.

22 employees
Industrial, Automotive
Nanopath vs
gMendel
gMendel Denmark

Transforming the diagnosis of genetic disorders for better disease management

9 employees

FAQ About Nanopath

Diagnostics for women.
Nanopath was founded in 2019.
Nanopath is headquartered in Cambridge, United States.
Nanopath operates in the following industries: Biotechnology.
Nanopath has approximately 18 employees.
Nanopath has completed 3 funding rounds, raising a total of $14.26M. The latest funding stage is Grant.
Top alternatives and competitors to Nanopath include Abrites, Eclipse Diagnostics, gMendel, Zalma Ltd., Gemelli Biotech. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Nanopath and Abrites are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Nanopath and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy

Book a demo 30 minutes